Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience
- PMID: 20490669
- DOI: 10.1007/s11255-010-9756-1
Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience
Abstract
Introduction: Chronic hepatitis C infection is common among patients on dialysis. While the associated liver disease is usually relatively mild during dialysis, disease progression can accelerate due to immunosuppression following kidney transplantation, and interferon therapy after transplantation stimulates graft rejection. Pegylated interferon and ribavirin are now the recommended treatment for chronic hepatitis C virus in patients without renal failure. However, until now, there has been relatively little information on the efficacy and tolerability of pegylated interferon in dialysis patients.
Aim of the work: To evaluate the response to pegylated interferon alpha-2a in chronic hepatitis C-infected patients on chronic hemodialysis.
Patients and methods: This controlled study included 28 patients with end-stage renal disease who had been on dialysis in the Prince Salman Center for Kidney Disease for more than 6 months and tested positive for HCV RNA on repeated occasions. Thirteen patients were treated with pegylated interferon alpha-2a therapy (of which three were also receiving ribavirin), and the remaining fifteen served as controls. Viral genotyping and both qualitative and quantitative PCR were carried out before starting therapy. Treatment was continued for 48 weeks. After 24 weeks of treatment, the biochemical and virological responses were evaluated. Biochemical response was evaluated at the end of the treatment, with sustained virological response (SVR) being evaluated 24 weeks later. The side effects were monitored throughout the treatment period.
Results: All patients in the treatment group completed 48 weeks of therapy without any drop out. Their mean age was 43.38 ± 11.62 years. After 24 weeks of therapy, 10 patients (76%) were initial responders, while 3 patients (24%) were resistant. Six months after termination of therapy, 9 patients (69%) were sustained responders, while one patient relapsed. Their ALT and AST dropped from 55.78 ± 33.79 IU/dl and 34.04 ± 19.58 IU/dl before starting therapy to 27.22 ± 16.54 IU/dl and 18.88 ± 12.28 IU/dl after termination (P = .06 and .08, respectively). Their mean hemoglobin (Hb) level dropped from 11.05 ± 1.43 to 9.48 ± 1.24 g/dl (P = 0.3), and white blood cell count (WBC) dropped from 6.82 ± 2.6 × 10(3)/mm(3) to 4.1 ± 2.34 × 10(3)/mm(3); (P = 0.57). Platelet count fell from 194.56 ± 129.78 × 10(3)/mm(3) to (152.33 ± 107.66 × 10(3)/mm(3); P = 0.39). When initial responders (n = 10) were compared to resistant patients (n = 3), the only observable difference was higher ALT and AST levels in resistant patients. Pegylated interferon alpha-2a was well tolerated, and none of the patients stopped interferon because of hematological side effects while dose modification was carried out in most of the patients. All three patients who received combination therapy from the start were sustained responders. None of the patients in the control group seroconverted to HCV negative status during the study period.
Conclusion: Pegylated interferon alpha-2a was well tolerated among our hemodialysis patients. Hematological disturbances appeared to be the most important adverse effects. At the end of therapy a response rate of up to 76%, with 69% sustained response, can be obtained with pegylated interferon alpha-2a therapy.
Similar articles
-
Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.Gene. 2014 Jul 10;544(2):101-6. doi: 10.1016/j.gene.2014.04.072. Epub 2014 May 1. Gene. 2014. PMID: 24793583 Review.
-
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.Ann Intern Med. 2013 Dec 3;159(11):729-38. doi: 10.7326/0003-4819-159-11-201312030-00005. Ann Intern Med. 2013. PMID: 24297189 Clinical Trial.
-
Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.Ren Fail. 2013;35(10):1305-9. doi: 10.3109/0886022X.2013.826136. Epub 2013 Sep 24. Ren Fail. 2013. PMID: 24059964 Clinical Trial.
-
Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.Ann Saudi Med. 2009 Jan-Feb;29(1):4-14. doi: 10.4103/0256-4947.51816. Ann Saudi Med. 2009. PMID: 19139619 Free PMC article.
-
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. doi: 10.3310/hta8390. Health Technol Assess. 2004. PMID: 15461877 Review.
Cited by
-
Seroprevalence of hepatitis C virus in Jinan, China, 2008-2020.Eur J Med Res. 2023 Mar 9;28(1):112. doi: 10.1186/s40001-023-01063-0. Eur J Med Res. 2023. PMID: 36894961 Free PMC article.
-
Management of hepatitis C in patients with chronic kidney disease.World J Gastroenterol. 2015 Jan 14;21(2):408-22. doi: 10.3748/wjg.v21.i2.408. World J Gastroenterol. 2015. PMID: 25593456 Free PMC article. Review.
-
Hepatitis C virus infection and dialysis: 2012 update.ISRN Nephrol. 2012 Dec 17;2013:159760. doi: 10.5402/2013/159760. eCollection 2013. ISRN Nephrol. 2012. PMID: 24959533 Free PMC article. Review.
-
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Int J Nanomedicine. 2014 Apr 25;9:2051-67. doi: 10.2147/IJN.S41822. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24812506 Free PMC article. Review.
-
SASLT practice guidelines: management of hepatitis C virus infection.Saudi J Gastroenterol. 2012 Sep;18 Suppl(Suppl 1):S1-32. doi: 10.4103/1319-3767.101155. Saudi J Gastroenterol. 2012. PMID: 23006491 Free PMC article. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials